Williams-Sonoma, Inc. (WSM) Stock Price Today
Defence Therapeutics appoints Sherry Aulin to Board, boosting expertise in finance and biotech.
Defence Therapeutics, a biotech company focused on precision oncology, has appointed Sherry Aulin to its Board of Directors and Audit Committee. Aulin brings over 20 years of finance experience, including a decade as CFO of Xenon Pharmaceuticals, whe...
Ondine Biomedical partners with NHS to prove Steriwave cuts hospital infections and saves costs fast
Ondine Biomedical has partnered with Mela Solutions, whose software is used in 90% of NHS intensive care units, to help hospitals quickly assess the cost-saving impact of its Steriwave antimicrobial treatment. Steriwave uses light to activate a treat...
Ketamine-based alcohol treatment cuts heavy drinking days by 67%, outperforming some existing drugs in analysis
Solvonis Therapeutics reported that its ketamine-based treatment, SVN-001, reduced heavy drinking days by 67% compared to placebo over four months after treatment, based on a phase II trial analysis. This reduction surpasses results seen with naltrex...
TempraMed signs LOI for exclusive distribution of VIVI Cap™ and VIVI Epi™ in Cyprus with CPO Cyprus.
TempraMed Technologies has signed a non-binding letter of intent with Cyprus Pharmaceutical Organization Ltd. (CPO Cyprus) to appoint them as the exclusive distributor of TempraMed's temperature-sensitive medication products, VIVI Cap™ and VIVI Epi™,...
Foundayo 17.2 mg outperforms oral semaglutide 25 mg in weight loss and blood sugar control for type 2 diabetes.
Eli Lilly's Foundayo (orforglipron) 17.2 mg showed significantly greater weight loss (1.5% more) and A1C reduction (0.3% more) than oral semaglutide 25 mg after 52 weeks in adults with type 2 diabetes, based on an indirect comparison of ACHIEVE-3 and...
AstraZeneca invests $2B in Summit Therapeutics for cancer drug collaboration and trials
AstraZeneca is investing $2 billion in Summit Therapeutics to collaborate on cancer drug development, acquiring about 12% of Summit's common stock. The partnership will start clinical trials combining Summit’s ivonescimab with AstraZeneca’s sonesitat...
IBM shares fall 16% since June but no fundamental issues seen, potential for value growth remains.
IBM's stock has dropped about 16% since mid-June, significantly underperforming the market. Despite this decline, there are no structural problems identified with the company. Strong institutional demand and undervaluation suggest that IBM could see ...
Anthropic warns AI risks while planning $2tn IPO amid soaring losses and revenue growth
Anthropic's IPO prospectus reveals serious warnings about AI risks, including potential catastrophic harm and rogue behavior from its models. Despite these risks, the company, known for its Claude chatbot, aims for a $2tn valuation with revenue growi...
Evotec's Chief Scientific Officer Dr. Cord Dohrmann to step down in 2026, search for successor underway
Evotec SE announced that Dr. Cord Dohrmann will step down as Chief Scientific Officer on September 30, 2026, after 16 years with the company. His leadership significantly advanced Evotec's scientific capabilities and innovation culture, particularly ...
Anthropic warns its AI could pose existential risks while planning a $2T IPO with soaring revenue and costs.
Anthropic's IPO prospectus reveals significant risks, including its AI models potentially resisting shutdown and manipulating information, raising existential concerns. Despite these warnings, the company projects a valuation over $2 trillion, with r...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.